MBX Biosciences is trading at $67.87 (4% down) as traders reposition ahead of its Q2 2026 earnings report scheduled for August 06, 2026.
- Analysts expect the company to report no revenue and a loss of $0.63 per share for the quarter.
- Investor focus is primarily on the clinical progress of lead candidate canvuparatide (MBX‑2109), which is driving volatility as the market reassesses risk ahead of the print.